APO Research
Talk to an analyst

APO RESEARCH · REPORT

Specific COX-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Specific COX-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchSpecific COX-2 Inhibitors Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Specific COX-2 Inhibitors Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Specific COX-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Specific COX-2 Inhibitors Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Specific COX-2 Inhibitors Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Specific COX-2 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Specific COX-2 Inhibitors include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Specific COX-2 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Specific COX-2 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Specific COX-2 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Specific COX-2 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Specific COX-2 Inhibitors Segment by Company

Actavis

Eskayef Pharmaceuticals

Mylan Pharmaceutical

Neopharmed Gentili

Organon Pharma

Pfizer

Teva

Zentiva

Zydus

Beijing Yabao Biological Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Jiangsu Chiatai Qingjiang Pharmaceutical

Qilu Pharmaceutical

Qingdao Baheal Medical

Shanxi Tongda Pharmaceutical

Sichuan Kelun Pharmaceutical

Specific COX-2 Inhibitors Segment by Type

Etoricoxib

Celecoxib

Imrecoxib

Other

Specific COX-2 Inhibitors Segment by Application

Osteoarthritis and Rheumatoid Arthritis

Relieve Acute Pain

Dysmenorrhea

Other

Specific COX-2 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Specific COX-2 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Specific COX-2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Specific COX-2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Specific COX-2 Inhibitors Industry Trends Table 2. Specific COX-2 Inhibitors Industry Drivers Table 3. Specific COX-2 Inhibitors Industry Opportunities and Challenges Table 4. Specific COX-2 Inhibitors Industry Restraints Table 5. Global Specific COX-2 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Specific COX-2 Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers Table 9. Global Specific COX-2 Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Specific COX-2 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Specific COX-2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Specific COX-2 Inhibitors Manufacturers, Product Type & Application Table 13. Global Specific COX-2 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Specific COX-2 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Etoricoxib Table 17. Major Manufacturers of Celecoxib Table 18. Major Manufacturers of Imrecoxib Table 19. Major Manufacturers of Other Table 20. Global Specific COX-2 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 22. Global Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 23. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global Specific COX-2 Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global Specific COX-2 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (K Units) Table 27. Global Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (K Units) Table 28. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Osteoarthritis and Rheumatoid Arthritis Table 31. Major Manufacturers of Relieve Acute Pain Table 32. Major Manufacturers of Dysmenorrhea Table 33. Major Manufacturers of Other Table 34. Global Specific COX-2 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 36. Global Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 37. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2026) Table 38. Global Specific COX-2 Inhibitors Sales Market Share by Application (2027-2032) Table 39. Global Specific COX-2 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (K Units) Table 41. Global Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (K Units) Table 42. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2026) Table 43. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2027-2032) Table 44. Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Specific COX-2 Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Specific COX-2 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 51. North America Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 52. Europe Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 54. Europe Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Specific COX-2 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Specific COX-2 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2026) Table 65. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2027-2032) Table 66. Actavis Company Information Table 67. Actavis Business Overview Table 68. Actavis Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Actavis Specific COX-2 Inhibitors Product Portfolio Table 70. Actavis Recent Development Table 71. Eskayef Pharmaceuticals Company Information Table 72. Eskayef Pharmaceuticals Business Overview Table 73. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 75. Eskayef Pharmaceuticals Recent Development Table 76. Mylan Pharmaceutical Company Information Table 77. Mylan Pharmaceutical Business Overview Table 78. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 80. Mylan Pharmaceutical Recent Development Table 81. Neopharmed Gentili Company Information Table 82. Neopharmed Gentili Business Overview Table 83. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio Table 85. Neopharmed Gentili Recent Development Table 86. Organon Pharma Company Information Table 87. Organon Pharma Business Overview Table 88. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Organon Pharma Specific COX-2 Inhibitors Product Portfolio Table 90. Organon Pharma Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pfizer Specific COX-2 Inhibitors Product Portfolio Table 95. Pfizer Recent Development Table 96. Teva Company Information Table 97. Teva Business Overview Table 98. Teva Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Teva Specific COX-2 Inhibitors Product Portfolio Table 100. Teva Recent Development Table 101. Zentiva Company Information Table 102. Zentiva Business Overview Table 103. Zentiva Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Zentiva Specific COX-2 Inhibitors Product Portfolio Table 105. Zentiva Recent Development Table 106. Zydus Company Information Table 107. Zydus Business Overview Table 108. Zydus Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Zydus Specific COX-2 Inhibitors Product Portfolio Table 110. Zydus Recent Development Table 111. Beijing Yabao Biological Pharmaceutical Company Information Table 112. Beijing Yabao Biological Pharmaceutical Business Overview Table 113. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 115. Beijing Yabao Biological Pharmaceutical Recent Development Table 116. Jiangsu Hengrui Pharmaceuticals Company Information Table 117. Jiangsu Hengrui Pharmaceuticals Business Overview Table 118. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 120. Jiangsu Hengrui Pharmaceuticals Recent Development Table 121. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information Table 122. Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview Table 123. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 125. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Development Table 126. Qilu Pharmaceutical Company Information Table 127. Qilu Pharmaceutical Business Overview Table 128. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 130. Qilu Pharmaceutical Recent Development Table 131. Qingdao Baheal Medical Company Information Table 132. Qingdao Baheal Medical Business Overview Table 133. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio Table 135. Qingdao Baheal Medical Recent Development Table 136. Shanxi Tongda Pharmaceutical Company Information Table 137. Shanxi Tongda Pharmaceutical Business Overview Table 138. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 140. Shanxi Tongda Pharmaceutical Recent Development Table 141. Sichuan Kelun Pharmaceutical Company Information Table 142. Sichuan Kelun Pharmaceutical Business Overview Table 143. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 145. Sichuan Kelun Pharmaceutical Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Specific COX-2 Inhibitors Distributors List Table 149. Specific COX-2 Inhibitors Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Specific COX-2 Inhibitors Product Image Figure 2. Global Specific COX-2 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Specific COX-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Specific COX-2 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Specific COX-2 Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Specific COX-2 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Etoricoxib Image Figure 9. Celecoxib Image Figure 10. Imrecoxib Image Figure 11. Other Image Figure 12. Global Specific COX-2 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Specific COX-2 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global Specific COX-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Specific COX-2 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Osteoarthritis and Rheumatoid Arthritis Image Figure 19. Relieve Acute Pain Image Figure 20. Dysmenorrhea Image Figure 21. Other Image Figure 22. Global Specific COX-2 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Specific COX-2 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032) Figure 25. Global Specific COX-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Specific COX-2 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032) Figure 28. North America Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032) Figure 30. U.S. Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032) Figure 35. Germany Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032) Figure 42. China Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032) Figure 50. Brazil Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Specific COX-2 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Specific COX-2 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Specific COX-2 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. North America Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. Europe Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Specific COX-2 Inhibitors Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Specific COX-2 Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Etoricoxib
  • Celecoxib
  • Imrecoxib
  • Other
Applications
  • Osteoarthritis and Rheumatoid Arthritis
  • Relieve Acute Pain
  • Dysmenorrhea
  • Other
Companies covered
  • Actavis
  • Eskayef Pharmaceuticals
  • Mylan Pharmaceutical
  • Neopharmed Gentili
  • Organon Pharma
  • Pfizer
  • Teva
  • Zentiva
  • Zydus
  • Beijing Yabao Biological Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Jiangsu Chiatai Qingjiang Pharmaceutical
  • Qilu Pharmaceutical
  • Qingdao Baheal Medical
  • Shanxi Tongda Pharmaceutical
  • Sichuan Kelun Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Specific COX-2 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Specific COX-2 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Specific COX-2 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Specific COX-2 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Specific COX-2 Inhibitors Market Dynamics
  1. 2.1 Specific COX-2 Inhibitors Industry Trends
  2. 2.2 Specific COX-2 Inhibitors Industry Drivers
  3. 2.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Specific COX-2 Inhibitors Industry Restraints
3 Specific COX-2 Inhibitors Market by Manufacturers
  1. 3.1 Global Specific COX-2 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Specific COX-2 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Specific COX-2 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Specific COX-2 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Specific COX-2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Specific COX-2 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Specific COX-2 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Specific COX-2 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Specific COX-2 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Specific COX-2 Inhibitors Tier 1, Tier 2, and Tier 3
4 Specific COX-2 Inhibitors Market by Type
  1. 4.1 Specific COX-2 Inhibitors Type Introduction
  2. 4.1.1 Etoricoxib
  3. 4.1.2 Celecoxib
  4. 4.1.3 Imrecoxib
  5. 4.1.4 Other
  6. 4.2 Global Specific COX-2 Inhibitors Sales by Type
  7. 4.2.1 Global Specific COX-2 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Specific COX-2 Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global Specific COX-2 Inhibitors Revenue by Type
  11. 4.3.1 Global Specific COX-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032)
5 Specific COX-2 Inhibitors Market by Application
  1. 5.1 Specific COX-2 Inhibitors Application Introduction
  2. 5.1.1 Osteoarthritis and Rheumatoid Arthritis
  3. 5.1.2 Relieve Acute Pain
  4. 5.1.3 Dysmenorrhea
  5. 5.1.4 Other
  6. 5.2 Global Specific COX-2 Inhibitors Sales by Application
  7. 5.2.1 Global Specific COX-2 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Specific COX-2 Inhibitors Sales by Application (2021-2032)
  9. 5.2.3 Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032)
  10. 5.3 Global Specific COX-2 Inhibitors Revenue by Application
  11. 5.3.1 Global Specific COX-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  13. 5.3.3 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Specific COX-2 Inhibitors Sales by Region
  1. 6.1 Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Specific COX-2 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Specific COX-2 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Specific COX-2 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Specific COX-2 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Specific COX-2 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Specific COX-2 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Specific COX-2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Specific COX-2 Inhibitors Revenue by Region
  1. 7.1 Global Specific COX-2 Inhibitors Revenue by Region
  2. 7.1.1 Global Specific COX-2 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Specific COX-2 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Specific COX-2 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Specific COX-2 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Specific COX-2 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Specific COX-2 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Specific COX-2 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Specific COX-2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Actavis
  2. 8.1.1 Actavis Company Information
  3. 8.1.2 Actavis Business Overview
  4. 8.1.3 Actavis Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
  6. 8.1.5 Actavis Recent Developments
  7. 8.2 Eskayef Pharmaceuticals
  8. 8.2.1 Eskayef Pharmaceuticals Company Information
  9. 8.2.2 Eskayef Pharmaceuticals Business Overview
  10. 8.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  12. 8.2.5 Eskayef Pharmaceuticals Recent Developments
  13. 8.3 Mylan Pharmaceutical
  14. 8.3.1 Mylan Pharmaceutical Company Information
  15. 8.3.2 Mylan Pharmaceutical Business Overview
  16. 8.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  18. 8.3.5 Mylan Pharmaceutical Recent Developments
  19. 8.4 Neopharmed Gentili
  20. 8.4.1 Neopharmed Gentili Company Information
  21. 8.4.2 Neopharmed Gentili Business Overview
  22. 8.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
  24. 8.4.5 Neopharmed Gentili Recent Developments
  25. 8.5 Organon Pharma
  26. 8.5.1 Organon Pharma Company Information
  27. 8.5.2 Organon Pharma Business Overview
  28. 8.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
  30. 8.5.5 Organon Pharma Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Zentiva
  44. 8.8.1 Zentiva Company Information
  45. 8.8.2 Zentiva Business Overview
  46. 8.8.3 Zentiva Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
  48. 8.8.5 Zentiva Recent Developments
  49. 8.9 Zydus
  50. 8.9.1 Zydus Company Information
  51. 8.9.2 Zydus Business Overview
  52. 8.9.3 Zydus Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
  54. 8.9.5 Zydus Recent Developments
  55. 8.10 Beijing Yabao Biological Pharmaceutical
  56. 8.10.1 Beijing Yabao Biological Pharmaceutical Company Information
  57. 8.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
  58. 8.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  60. 8.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
  61. 8.11 Jiangsu Hengrui Pharmaceuticals
  62. 8.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 8.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 8.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  66. 8.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 8.12 Jiangsu Chiatai Qingjiang Pharmaceutical
  68. 8.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
  69. 8.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
  70. 8.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  72. 8.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
  73. 8.13 Qilu Pharmaceutical
  74. 8.13.1 Qilu Pharmaceutical Company Information
  75. 8.13.2 Qilu Pharmaceutical Business Overview
  76. 8.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  78. 8.13.5 Qilu Pharmaceutical Recent Developments
  79. 8.14 Qingdao Baheal Medical
  80. 8.14.1 Qingdao Baheal Medical Company Information
  81. 8.14.2 Qingdao Baheal Medical Business Overview
  82. 8.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
  84. 8.14.5 Qingdao Baheal Medical Recent Developments
  85. 8.15 Shanxi Tongda Pharmaceutical
  86. 8.15.1 Shanxi Tongda Pharmaceutical Company Information
  87. 8.15.2 Shanxi Tongda Pharmaceutical Business Overview
  88. 8.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  90. 8.15.5 Shanxi Tongda Pharmaceutical Recent Developments
  91. 8.16 Sichuan Kelun Pharmaceutical
  92. 8.16.1 Sichuan Kelun Pharmaceutical Company Information
  93. 8.16.2 Sichuan Kelun Pharmaceutical Business Overview
  94. 8.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  96. 8.16.5 Sichuan Kelun Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Specific COX-2 Inhibitors Value Chain Analysis
  2. 9.1.1 Specific COX-2 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Specific COX-2 Inhibitors Production Mode & Process
  6. 9.2 Specific COX-2 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Specific COX-2 Inhibitors Distributors
  9. 9.2.3 Specific COX-2 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst